Skip to main content Accessibility help
×
Home

Effectiveness of cognitive–behavioural therapy for depression in advanced cancer: CanTalk randomised controlled trial

  • Marc Serfaty (a1), Michael King (a2), Irwin Nazareth (a3), Stirling Moorey (a4), Trefor Aspden (a5), Kathryn Mannix (a6), Sarah Davis (a7), John Wood (a8) and Louise Jones (a9)...

Abstract

Background

Depression is one of the most common mental disorders in people with advanced cancer. Although cognitive–behavioural therapy (CBT) has been shown to be effective for depression in people with cancer, it is unclear whether this is the case for people with advanced cancer and depression.

Aims

We sought to determine whether CBT is more clinically effective than treatment as usual (TAU) for treating depression in people with advanced cancer (trial registration number ISRCTN07622709).

Method

A multi-centre, parallel-group single-blind randomised controlled trial comparing TAU with CBT (plus TAU). Participants (n = 230) with advanced cancer and depression were randomly allocated to (a) up to 12 sessions of individual CBT or (b) TAU. The primary outcome measure was the Beck Depression Inventory-II (BDI-II). Secondary outcome measures included the Patient Health Questionnaire-9, the Eastern Cooperative Oncology Group Performance Status, and Satisfaction with Care.

Results

Multilevel modelling, including complier-average intention-to-treat analysis, found no benefit of CBT. CBT delivery was proficient, but there was no treatment effect (−0.84, 95% CI −2.76 to 1.08) or effects for secondary measures. Exploratory subgroup analysis suggested an effect of CBT on the BDI-II in those widowed, divorced or separated (−7.21, 95% CI −11.15 to −3.28).

Conclusions

UK National Institute for Health and Care Excellence (NICE) guidelines recommend CBT for treating depression. Delivery of CBT through the Improving Access to Psychological Therapies (IAPT) programme has been advocated for long-term conditions such as cancer. Although it is feasible to deliver CBT through IAPT proficiently to people with advanced cancer, this is not clinically effective. CBT for people widowed, divorced or separated needs further exploration. Alternate models of CBT delivery may yield different results.

Declaration of interest

M.S. is a member of the Health Technology Assessment General Board.

Copyright

Corresponding author

Correspondence: Dr Marc Serfaty, Division of Psychiatry, University College London, 6th Floor Maple House, 149 Tottenham Court Road, London W1T 7NF, UK. Email: m.serfaty@ucl.ac.uk

References

Hide All
1Mitchell, AJ, Chan, M, Bhatti, H, Halton, M, Grassi, L, Johansen, C, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol 2011; 12: 160–74.
2Lloyd-Williams, M, Shiels, C, Taylor, F, Dennis, M. Depression: an independent predictor of early death in patients with advanced cancer. J Affect Disord 2009; 113: 127–32.
3National Institute for Health and Care Excellence. Improving Outcomes in Supportive and Palliative Care for Adults with Cancer. NICE, 2004.
4Pitman, A, Suleman, S, Hyde, N, Hodgkiss, A. Depression and anxiety in patients with cancer. BMJ 2018; 361: k1415.
5Price, A, Hotopf, M. The treatment of depression in patients with advanced cancer undergoing palliative care. Curr Opin Support Palliat Care 2009; 3: 61–6.
6Mustafa, M, Carson-Stevens, A, Gillespie, D, Edwards, AG. Psychological interventions for women with metastatic breast cancer. Cochrane Database Syst Rev 2013; 6: CD004253.
7Serfaty, M, King, M, Nazareth, I, Moorey, S, Aspden, T, Tookman, A, et al. Manualised cognitive-behavioural therapy in treating depression in advanced cancer: the CanTalk RCT. Health Technol Assess 2019; 23(19): 1106.
8Serfaty, M, King, M, Nazareth, I, Tookman, A, Wood, J, Gola, A, et al. The clinical and cost effectiveness of cognitive behavioural therapy plus treatment as usual for the treatment of depression in advanced cancer (CanTalk): study protocol for a randomised controlled trial. Trials 2016; 17: 113.
9Kroenke, K, Spitzer, RL. The PHQ-9: a new depression diagnostic and severity measure. Psychiatr Ann 2002; 32: 509–15.
10Sheehan, DV, Lecrubier, Y, Sheehan, KH, Amorim, P, Janavs, J, Weiller, E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59(suppl 20): 2233.
11Saunders, JB, Aasland, OG, Babor, TF, de la Fuente, JR, Grant, M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction 1993; 88: 791804.
12.Department of Health. Talking Therapies: A Four-Year Plan of Action. Department of Health, 2011.
13Beck, AT. Cognitive Therapy of Depression. Guilford Press, 1979.
14Blackburn, I-M, James, IA, Milne, DL, Baker, C. The Revised Cognitive Therapy Scale (CTS-R): psychometric properties. Behav Cogn Psychother 2001; 29: 431–46.
15Beck, A, Steer, R, Brown, G. BDI-II, Beck Depression Inventory: Manual. Psychological Corporation, 1996.
16Laidlaw, T, Bennett, BM, Dwivedi, P, Naito, A, Gruzelier, J. Quality of life and mood changes in metastatic breast cancer after training in self-hypnosis or Johrei: a short report. Contemp Hypn 2005; 22: 8493.
17Kroenke, K, Spitzer, RL, Williams, JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16: 606–13.
18Brooks, R. EuroQol: the current state of play. Health Policy 1996; 37: 5372.
19King, M, Jones, L, Richardson, A, Murad, S, Irving, A, Aslett, H, et al. The relationship between patients’ experiences of continuity of cancer care and health outcomes: a mixed methods study. Br J Cancer 2008; 98: 529–36.
20Oken, MM, Creech, RH, Tormey, DC, Horton, J, Davis, TE, McFadden, ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–56.
21Bollini, P, Pampallona, S, Tibaldi, G, Kupelnick, B, Munizza, C. Effectiveness of antidepressants: meta-analysis of dose-effect relationships in randomised clinical trials. Br J Psychiatry 1999; 174: 297303.
22Kessler, D, Lewis, G, Kaur, S, Wiles, N, King, M, Weich, S, et al. Therapist-delivered internet psychotherapy for depression in primary care: a randomised controlled trial. Lancet 2009; 374: 628–34.
23Sussman, J, Hayward, R. An IV for the RCT: using instrumental variables to adjust for treatment contamination in randomised controlled trials. BMJ 2009; 340: c2073.
24Hayasaka, Y, Purgato, M, Magni, LR, Ogawa, Y, Takeshima, N, Cipriani, A, et al. Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. J Affect Disord 2015; 180: 179–84.
25Fournier, JC, DeRubeis, RJ, Shelton, RC, Hollon, SD, Amsterdam, JD, Gallop, R. Prediction of response to medication and cognitive therapy in the treatment of moderate to severe depression. J Consult Clin Psychol 2009; 77: 775–87.
26Walker, J, Hansen, CH, Martin, P, Symeonides, S, Gourley, C, Wall, L, et al. Integrated collaborative care for major depression comorbid with a poor prognosis cancer (SMaRT Oncology-3): a multicentre randomised controlled trial in patients with lung cancer. Lancet Oncol 2014; 15: 1168–76.
27Rodin, G, Lo, C, Rydall, A, Shnall, J, Malfitano, C, Chiu, A, et al. Managing Cancer And Living Meaningfully (CALM): a randomized controlled trial of a psychological intervention for patients with advanced cancer. J Clin Oncol 2018; 36: 2422–32.
28Kroenke, K. Enhancing the clinical utility of depression screening. Can Med Assoc J 2012; 184: 281–2.
29Cuijpers, P, Berking, M, Andersson, G, Quigley, L, Kleiboer, A, Dobson, KS. A meta-analysis of cognitive-behavioural therapy for adult depression, alone and in comparison with other treatments. Can J Psychiatry 2013; 58: 376–85.
30Savard, J, Simard, S, Giguère, I, Ivers, H, Morin, CM, Maunsell, E, et al. Randomized clinical trial on cognitive therapy for depression in women with metastatic breast cancer: psychological and immunological effects. Palliat Support Care 2006; 4: 219–37.
31Moorey, S, Cort, E, Kapari, M, Monroe, B, Hansford, P, Mannix, K, et al. A cluster randomized controlled trial of cognitive behaviour therapy for common mental disorders in patients with advanced cancer. Psychol Med 2009; 39: 713–23.
32Hassan, S, Bennett, K, Serfaty, M. Delivering cognitive behavioural therapy to advanced cancer patients: a qualitative exploration into therapists’ experiences within a UK psychological service. Clin Psychol Psychother 2018; Mar 25: doi 10.1002/cpp.2190 [Epub ahead of print].
33Department of Health. A Mandate from the Government to NHS England: April 2014 to March 2015. Department of Health, 2015.
34Glover, G, Webb, M, Evison, F. Improving Access to Psychological Therapies: A Review of the Progress Made by Sites in the First Roll-Out Year. North East Public Health Observatory, 2010.
35Ostuzzi, G, Matcham, F, Dauchy, S, Barbui, C, Hotopf, M. Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev 2018; 4: CD011006.

Keywords

Type Description Title
WORD
Supplementary materials

Serfaty et al. supplementary material
Tables S1-S2

 Word (34 KB)
34 KB

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Effectiveness of cognitive–behavioural therapy for depression in advanced cancer: CanTalk randomised controlled trial

  • Marc Serfaty (a1), Michael King (a2), Irwin Nazareth (a3), Stirling Moorey (a4), Trefor Aspden (a5), Kathryn Mannix (a6), Sarah Davis (a7), John Wood (a8) and Louise Jones (a9)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *